Protagenic Gross Profit from 2010 to 2024

PTIXW Stock

USD 0.01 0.00 0.00%

Protagenic Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Protagenic Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1995-09-30

Previous Quarter

-12.6 K

Current Value

25.1 K

Quarterly Volatility

3.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Protagenic Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Protagenic Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Protagenic Therapeutics minus its cost of goods sold. It is profit before Protagenic Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Protagenic Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Protagenic Gross Profit Regression Statistics

	Arithmetic Mean	240,777
	Geometric Mean	1,804
	Coefficient Of Variation	374.72
	Mean Deviation	434,563
	Median	(339.00)
	Standard Deviation	902,234
	Sample Variance	814B
	Range	3.5M
	R-Value	(0.46)
	Mean Square Error	693.9B
	R-Squared	0.21
	Significance	0.09
	Slope	(92,103)
	Total Sum of Squares	11.4T

Protagenic Gross Profit History

	2024	-26.8 K
	2023	-28.2 K
	2021	-30.0
	2020	-286.0
	2019	-339.0
	2018	-347.0
	2017	-148.0

Other Fundumenentals of Protagenic Therapeutics

Gross Profit Margin

Protagenic Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Intangible Assets	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt	Capital Surpluse	Short Long Term Debt
Total Assets		0.63	-0.02	0.19	-0.48	-0.48	-0.17	0.88	0.12	-0.24	-0.24	0.81	-0.27	0.57	0.73	0.73	0.11	-0.1	-0.09	-0.09
Total Stockholder Equity	0.63		-0.54	0.85	-0.16	-0.16	-0.87	0.64	-0.66	-0.9	-0.89	0.53	0.03	0.26	0.49	0.49	-0.03	0.07	-0.26	-0.26
Net Debt	-0.02	-0.54		-0.55	-0.42	-0.42	0.66	-0.23	0.68	0.61	0.61	-0.06	-0.43	0.32	-0.12	-0.12	0.16	0.02	0.38	0.38
Retained Earnings	0.19	0.85	-0.55		-0.13	-0.13	-0.98	0.15	-0.84	-0.99	-0.99	0.09	-0.07	0.15	0.06	0.06	-0.01	0.1	-0.04	-0.04
Net Receivables	-0.48	-0.16	-0.42	-0.13		1.0	-0.07	-0.04	-0.41	0.04	0.05	0.0	0.82	-0.95	0.15	0.15	-0.2	0.18	-0.41	-0.41
Good Will	-0.48	-0.16	-0.42	-0.13	1.0		-0.07	-0.04	-0.41	0.04	0.05	0.0	0.82	-0.95	0.15	0.15	-0.2	0.18	-0.41	-0.41
Total Liab	-0.17	-0.87	0.66	-0.98	-0.07	-0.07		-0.22	0.91	0.99	0.99	-0.15	-0.12	0.01	-0.16	-0.15	0.08	-0.12	0.17	0.17
Total Current Assets	0.88	0.64	-0.23	0.15	-0.04	-0.04	-0.22		-0.07	-0.25	-0.24	0.92	0.19	0.17	0.89	0.89	0.05	0.01	-0.37	-0.37
Short Term Debt	0.12	-0.66	0.68	-0.84	-0.41	-0.41	0.91	-0.07		0.86	0.86	-0.08	-0.32	0.41	-0.14	-0.14	0.03	-0.17	0.13	0.13
Common Stock	-0.24	-0.9	0.61	-0.99	0.04	0.04	0.99	-0.25	0.86		1.0	-0.16	-0.04	-0.1	-0.15	-0.14	0.07	-0.16	0.15	0.15
Accounts Payable	-0.24	-0.89	0.61	-0.99	0.05	0.05	0.99	-0.24	0.86	1.0		-0.15	-0.03	-0.11	-0.14	-0.14	0.07	-0.15	0.14	0.14
Short Term Investments	0.81	0.53	-0.06	0.09	0.0	0.0	-0.15	0.92	-0.08	-0.16	-0.15		0.07	0.04	0.98	0.98	0.12	-0.14	-0.12	-0.12
Intangible Assets	-0.27	0.03	-0.43	-0.07	0.82	0.82	-0.12	0.19	-0.32	-0.04	-0.03	0.07		-0.64	0.16	0.16	-0.24	0.3	-0.79	-0.79
Current Deferred Revenue	0.57	0.26	0.32	0.15	-0.95	-0.95	0.01	0.17	0.41	-0.1	-0.11	0.04	-0.64		-0.1	-0.1	0.05	-0.11	0.1	0.1
Net Invested Capital	0.73	0.49	-0.12	0.06	0.15	0.15	-0.16	0.89	-0.14	-0.15	-0.14	0.98	0.16	-0.1		1.0	0.12	-0.09	-0.17	-0.17
Net Working Capital	0.73	0.49	-0.12	0.06	0.15	0.15	-0.15	0.89	-0.14	-0.14	-0.14	0.98	0.16	-0.1	1.0		0.15	-0.09	-0.16	-0.16
Capital Stock	0.11	-0.03	0.16	-0.01	-0.2	-0.2	0.08	0.05	0.03	0.07	0.07	0.12	-0.24	0.05	0.12	0.15		-0.06	0.42	0.42
Long Term Debt	-0.1	0.07	0.02	0.1	0.18	0.18	-0.12	0.01	-0.17	-0.16	-0.15	-0.14	0.3	-0.11	-0.09	-0.09	-0.06		-0.27	-0.27
Capital Surpluse	-0.09	-0.26	0.38	-0.04	-0.41	-0.41	0.17	-0.37	0.13	0.15	0.14	-0.12	-0.79	0.1	-0.17	-0.16	0.42	-0.27		1.0
Short Long Term Debt	-0.09	-0.26	0.38	-0.04	-0.41	-0.41	0.17	-0.37	0.13	0.15	0.14	-0.12	-0.79	0.1	-0.17	-0.16	0.42	-0.27	1.0

Click cells to compare fundamentals

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-28.2 K	-26.8 K
Gross Profit Margin	(0.08)	(0.07)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC